Document is current

Article History

Received: 14 October 2024

Accepted: 9 February 2025

First Online: 28 February 2025

Declarations

:

: The institutional review board (IRB) of KU Leuven (Belgium) waived the need for ethical approval as no personal information was collected. The study and the used QualtricsXM software adhere to the General Data Protection Regulation (GDPR) guidelines. Participation to the survey was voluntary and participants could decline to take part or leave the survey at any time. The information provided was kept completely confidential. The survey was analysed anonymously, and no e-mail addresses or IP addresses were collected as part of the survey. E-mail addresses were only used to distribute the survey and were not made available to the consortium. The data were only reported in an aggregated form.

: The authors explain that there are no issues relating to the journal’s policies and confirm that the content of the manuscript has not been published, or submitted for publication elsewhere. No images are personal or clinical details of participants are presented.

: Wim Wuyts: grants paid to institution from Roche, Sanofi, Alentis and Boehringer Ingelheim. - Liam Galvin and Steve Jones: unrestricted grants to EU-PFF from Boehringer Ingelheim, Roche, Trevi Therapeutics, Chiesi Pharmaceuticals, Bristol Meyer Squibb, Vicore Pharma, CSL Behring, and Ferrer.- Michael Kreuter: consulting fees from GSK, Boehringer, AstraZeneca, Pliant, and BMS. Yet, these authors declare that these disclosures did not influence the results and/or discussion reported in this paper.

: We hereby declare that AI has been used to ensure grammatical accuracy.